What podcasts say about Johnson & Johnson
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Johnson & Johnson
68 statements · 63 positive · 2 negative · 1 mixed · 2 neutral
The Allen transaction includes more than $1.1 billion in regulatory and commercial milestones.
“There's another 1.1 or a little more. in regulatory and commercial milestones.”
Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton OddsListen at 2:18
Johnson & Johnson is buying All In Biosciences for over $2 billion.
“the drugmaker is buying iDisease Biotech Company All In Biosciences for over $2 billion.”
Open the episode · NVIDIA's China Loophole & The Aviation Blame GameListen at 17:04
Johnson & Johnson will likely continue growth and dividend payments.
“I think you're gonna likely continue to see some growth, continue to see that dividend.”
Open the episode · Fast Money: FAA Ground Stop, Anthropic IPO and AI Market Rotation 11/13/26Listen at 37:29
Guy Adami holds a long position in Johnson & Johnson.
“I'm long.”
Open the episode · Nvidia Fallout, AI Financing Risk and Apple’s Safe-Haven SurgeListen at 28:46
Johnson & Johnson stock will rise.
“J&J is going higher.”
Open the episode · Nvidia Fallout, AI Financing Risk and Apple’s Safe-Haven SurgeListen at 42:14
Investors should own Johnson & Johnson stock.
“Own the stock.”
Open the episode · Mad Money w/ Jim Cramer 11/2/26Listen at 36:52
Johnson & Johnson’s pharmaceutical business is among the best positioned.
“J&J, even though the stock was down a lot yesterday because of issues they're having in medical devices, that pharma business within J&J looks to be one of the best.”
Open the episode · AI Trade Faces a Reality Check 10/14/26Listen at 26:59
Johnson & Johnson’s post-earnings decline was unjustified.
“I don't believe J&J deserved to get hit like this.”
Open the episode · Mad Money w/ Jim Cramer 10/13/26Listen at 19:54
Cramer remains bullish on Johnson & Johnson’s investment thesis.
“My overall thesis for J&J stands.”
Open the episode · Mad Money w/ Jim Cramer 10/13/26Listen at 24:48
Johnson & Johnson has one of the industry’s best drug portfolios.
“I think this company is one of the best drug portfolios in the industry.”
Open the episode · Mad Money w/ Jim Cramer 10/13/26Listen at 24:50
Johnson & Johnson is an attractive buying opportunity.
“The bottom line, I think this is a good chance to get into one of the best-performing pharma names out there”
Open the episode · Mad Money w/ Jim Cramer 10/13/26Listen at 25:50
Investors should consider buying Johnson & Johnson after its decline.
“it might be a good time to do some buying.”
Open the episode · Mad Money w/ Jim Cramer 10/13/26Listen at 26:04
Johnson & Johnson’s decline is a buying opportunity.
“So I think this is an opportunity.”
Open the episode · Drama in DRAM Memory ETF… And Trading Apple & Others At Record Highs… 10/13/26Listen at 26:40
Johnson & Johnson has moved beyond its patent cliff.
“J&J actually came out on the other side of the patent cliff.”
Open the episode · Drama in DRAM Memory ETF… And Trading Apple & Others At Record Highs… 10/13/26Listen at 27:02
Investors should use Johnson & Johnson’s pullback to buy.
“I think this pullback in J&J is actually a great chance to get in on one of the best-performing pharma stocks on the market right now.”
Open the episode · Mad Money w/ Jim Cramer 10/13/26Listen at 27:11
Johnson & Johnson ranks among America’s top twenty companies
“I am willing to say that J&J is a top 20 company in this country.”
Open the episode · Mad Money w/ Jim Cramer 10/9/26Listen at 4:06
Investors should buy Johnson & Johnson after sharp declines
“J&J needs to be bought when the stock gets crushed.”
Open the episode · Mad Money w/ Jim Cramer 10/9/26Listen at 4:47
Cramer recommends buying Johnson & Johnson.
“I buy that one.”
Open the episode · Mad Money w/ Jim Cramer 10/1/26Listen at 6:50
Johnson & Johnson ranks ahead of Eli Lilly and Pfizer
“So I'm going to say J&J, Lilly, and then Pfizer.”
Open the episode · Mad Money w/ Jim Cramer 9/3/26Listen at 27:22
Johnson & Johnson agreed to commit $5.5 billion toward resolving talc litigation.
“Johnson Johnson says it has agreed to a $5.5 billion commitment to resolve litigation related to claims that its talc products caused ovarian cancer.”
Open the episode · Johnson & Johnson Settlement; Barclays Reports; Applied Digital RalliesListen at 2:33
If signed, the Johnson & Johnson agreement will help close the long-running litigation issue.
“But but if it's signed, it will help close an issue that's been ongoing for at least 15 years.”
Open the episode · Johnson & Johnson Settlement; Barclays Reports; Applied Digital RalliesListen at 2:50
Johnson & Johnson’s technology business will matter in future years.
“Look out, J&J has tech, although it won't matter for a few years.”
Open the episode · Mad Money w/ Jim Cramer 7/22/26Listen at 3:59
Investors should buy Johnson & Johnson after its decline.
“I would take it.”
Open the episode · Mad Money w/ Jim Cramer 7/16/26Listen at 6:24
Long-term investors should favor Johnson & Johnson or Wells Fargo over margin-driven technology trades.
“It's much better to take advantage of a mismarked J&J or Wells Fargo for the long term”
Open the episode · Mad Money w/ Jim Cramer 7/16/26Listen at 8:53
Johnson & Johnson shares fell despite earnings beats and modestly raised 2026 guidance.
“Johnson and Johnson shares trading under ticker JNJ are down almost 2% in the premarket after the pharma company beat second quarter top and bottom line estimates and the company modestly raised its 2026 sales and profit guidance.”
Open the episode · IBM Historic Plunge; Financials Report; SpaceX Near IPO PriceListen at 1:00
Johnson & Johnson’s earnings beat was driven by drug growth in several therapeutic areas.
“The company's beat was driven by growth for its of cancer, inflammatory diseases and treatment resistant depression drugs.”
Open the episode · IBM Historic Plunge; Financials Report; SpaceX Near IPO PriceListen at 1:35
Johnson & Johnson’s results suggest drug makers are thriving despite regulatory and pricing pressures.
“This company is suggesting drug makers are thriving despite some recent turmoil at the FDA and some deals with the White House to lower net prices on some medicines.”
Open the episode · IBM Historic Plunge; Financials Report; SpaceX Near IPO PriceListen at 1:55
Cramer expects Johnson & Johnson stock to perform poorly.
“that's how I think the stock should perform.”
Open the episode · Mad Money w/ Jim Cramer 7/15/26Listen at 6:00
Johnson & Johnson will report favorable news about blockbuster drugs, especially oncology products.
“I think the company will have lots of good news about its myriad blockbuster drugs, especially its oncological franchise.”
Open the episode · Mad Money w/ Jim Cramer 7/6/26Listen at 3:43
Johnson & Johnson will report cardiovascular market-share gains.
“I expect some good news about share gains in cardio.”
Open the episode · Mad Money w/ Jim Cramer 7/6/26Listen at 3:48
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.